In the first four cohorts, all patients received sofosbuvir 400 mg once daily, plus RBV twice daily for 12 weeks. Groups 1–3 received PEG-IFN for 4, 8, and 12 weeks, respectively. Among the 40 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback